- A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignanciesMatthew A Gubens
University of California, San Francisco, CA, United States Electronic address
Lung Cancer 89:57-60. 2015..Src plays a role in normal thymic epithelial maturation, and its inhibition with the oral compound saracatinib was postulated to be effective in controlling thymic malignancy...
- Treatment updates in advanced thymoma and thymic carcinomaMatthew A Gubens
Thoracic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
Curr Treat Options Oncol 13:527-34. 2012..Greater international research collaboration, as well as modern techniques in molecular and genomic characterization, should help to advance the treatment of thymic malignancies in the near future...